STATUS OF THE CLAIMS:

1.-47. (Canceled)

48. (Previously Presented) A method for providing analgesia in a subject, said method comprising delivering a composition comprising fentanyl or a fentanyl congener to the subject, wherein the composition is administered to the subject using an implantable convective delivery system, is delivered from the system for 48 hours or more at a low volume rate of 2 ml/day or less and is sufficient to provide analgesia in the subject.

49. (Previously Presented) The method of claim 48, wherein the composition is delivered using a patterned delivery regime.

50. (Previously Presented) The method of claim 49, wherein the composition is delivered in a substantially continuous fashion.

51. (Previously Presented) The method of claim 49, wherein the composition is delivered in a substantially uninterrupted manner for a pre-selected period of time.

52. (Previously Presented) The method of claim 49, wherein the composition is delivered in a substantially constant fashion.

53. (Previously Presented) The method of claim 49, wherein the composition is delivered over an extended period of time.

54. (Previously Presented) The method of claim 53, wherein the composition is delivered for a period of about 72 hours.

55. (Previously Presented) The method of claim 53, wherein the composition is delivered for a period from 2 to 5 days.

56. (Previously Presented) The method of claim 53, wherein the composition is delivered for a period of at least about 100 days.

57. (Previously Presented) The method of claim 49, wherein the composition is delivered using a controlled drug delivery device.

58. (Previously Presented) The method of claim of claim 57, wherein the controlled delivery device is implanted in the subject's body.

59. (Previously Presented) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.01 µl/day to about 100 µl/day.

60. (Previously Presented) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.04 µl/day to about 10 µl/day.

61. (Previously Presented) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.2 µl/day to about 5 µl/day.

62. (Previously Presented) The method of claim 48, wherein the composition is delivered to the subject at a volume rate of from about 0.5 µl/day to about 1 µl/day.

63. (Previously Presented) A method for providing analgesia in a subject, said method comprising delivering to the subject a composition comprising fentanyl or a fentanyl congener, wherein said fentanyl or fentanyl congener is present in the composition at a concentration of about 0.5 mg/ml to about 500 mg/ml or greater, and further wherein the composition is administered to the subject using an implantable convective delivery system, is delivered from

the system at a low volume rate of about 2 ml/day or less and is sufficient to provide analgesia in the subject.

64. (Previously Presented) The method of claim 63, wherein the fentanyl or fentanyl congener is in solution.

65. (Previously Presented) The method of claim 64, wherein the fentanyl or fentanyl congener is dissolved in a liquid carrier.

66. (Previously Presented) The method of claim 63, wherein the composition is administered to the subject as a semi-solid, gel, liquid, suspension, emulsion or an osmotic dosage pharmaceutical formulation.

67. (Previously Presented) The method of claim 63, wherein the fentanyl or fentanyl congener is present in the composition at a concentration of at least about 2 to at least about 10,000 times greater than the solubility of fentanyl or fentanyl congener in aqueous solution.

68. (Previously Presented) The method of claim 63, wherein the fentanyl or fentanyl congener is present in the composition at a concentration of from about 0.5 mg/ml to about 500 mg/ml.

69. (Previously Presented) The method of claim 63, wherein the fentanyl or fentanyl congener is present in the composition at a concentration of from about 1 mg/ml to about 400 mg/ml.

70. (Previously Presented) The method of claim 63, wherein the fentanyl or fentanyl congener is present in the composition at a concentration of from about 50 mg/ml to about 400 mg/ml.

71. (Previously Presented) The method of claim 63, wherein the fentanyl or fentanyl congener is present in the composition at a concentration of from about 75 mg/ml to about 300 mg/ml.

72. (Previously Presented) The method of claim 63, wherein the fentanyl or fentanyl congener is present in the composition at a concentration of from about 100 mg/ml to about 250 mg/ml.

73. (Previously Presented) The method of claim 63, wherein the composition is delivered at a low volume rate of 2 ml/day or less.

74. (Previously Presented) The method of claim 63, wherein the composition is delivered using a patterned delivery regime.

75. (Previously Presented) The method of claim 74, wherein the composition is delivered in a substantially continuous fashion.

76. (Previously Presented) The method of claim 74, wherein the composition is delivered in a substantially uninterrupted manner for a pre-selected period of time.

77. (Previously Presented) The method of claim 74, wherein the composition is delivered in a substantially constant fashion.

78. (Previously Presented) The method of claim 74, wherein the composition is delivered over an extended period of time.

79. (Previously Presented) The method of claim 78, wherein the composition is delivered for a period from about 2 to about 48 hours.

80. (Previously Presented) The method of claim 78, wherein the composition is delivered for a period from about 2 to 5 days.

81. (Previously Presented) The method of claim 78, wherein the composition is delivered for a period of at least about 100 days.

82. (Previously Presented) The method of claim 74, wherein the composition is delivered using a controlled drug delivery device.

83. (Previously Presented) The method of claim of claim 82, wherein the controlled delivery device is implanted in the subject's body.

84. (Previously Presented) A method for providing analgesia in a subject, said method comprising delivering to the subject a composition comprising fentanyl or a fentanyl congener, wherein the composition is administered to the subject using an implantable convective delivery system, the composition is delivered from the system for 48 hours or more at a low volume rate sufficient to deliver from about 0.01 μg/hour to about 200 μg/hour of the fentanyl or fentanyl congener to the subject, and further wherein said amount of delivered fentanyl or fentanyl congener is sufficient to establish a systemic analgesic effect in the subject.

85. (Previously Presented) The method of claim 84, wherein the fentanyl or fentanyl congener is in solution.

86. (Previously Presented) The method of claim 85, wherein the fentanyl or fentanyl congener is dissolved in a liquid carrier.

87. (Previously Presented) The method of claim 84, wherein the composition is administered to the subject as a semi-solid, gel, liquid, suspension, emulsion or an osmotic dosage pharmaceutical formulation.

88. (Previously Presented) The method of claim 84, wherein the systemic analgesic effect is sufficient to manage pain in the subject.

89. (Previously Presented) The method of claim 84, wherein the systemic analgesic effect is sufficient to treat pain in the subject.

90. (Previously Presented) The method of claim 84, wherein the systemic analgesic effect is sufficient to modulate pain response in the subject.

91. (Previously Presented) The method of claim 84, wherein the systemic analgesic effect is sufficient to ameliorate or alleviate pain in the subject.

92. (Previously Presented) The method of claim 48, wherein the fentanyl congener is sufentanil.

93. (Previously Presented) The method of claim 63, wherein the fentanyl congener is sufentanil.

94. (Previously Presented) The method of claim 84, wherein the fentanyl congener is sufentanil.

95. (Previously Presented) The method of claim 68, wherein the fentanyl congener is sufentanil.

96. (Previously Presented) The method of claim 69, wherein the fentanyl congener is sufentanil.

97. (Previously Presented) The method of claim 70, wherein the fentanyl congener is sufentanil.

98. (Previously Presented) The method of claim 71, wherein the fentanyl congener is sufentanil.

99. (Previously Presented) The method of claim 72, wherein the fentanyl congener is sufentanil.